<code id='718AE0152A'></code><style id='718AE0152A'></style>
    • <acronym id='718AE0152A'></acronym>
      <center id='718AE0152A'><center id='718AE0152A'><tfoot id='718AE0152A'></tfoot></center><abbr id='718AE0152A'><dir id='718AE0152A'><tfoot id='718AE0152A'></tfoot><noframes id='718AE0152A'>

    • <optgroup id='718AE0152A'><strike id='718AE0152A'><sup id='718AE0152A'></sup></strike><code id='718AE0152A'></code></optgroup>
        1. <b id='718AE0152A'><label id='718AE0152A'><select id='718AE0152A'><dt id='718AE0152A'><span id='718AE0152A'></span></dt></select></label></b><u id='718AE0152A'></u>
          <i id='718AE0152A'><strike id='718AE0152A'><tt id='718AE0152A'><pre id='718AE0152A'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:explore    Page View:8264
          King Street Properties’ Pathway Devens campus. -- biotech coverage from STAT
          Pat Greenhouse/Globe Staff

          MORRISVILLE, N.C. — Ten minutes from the Raleigh airport, the future of biotech is under construction.

          On either side of a new stretch of four-lane highway sit two $1 billion biomanufacturing campuses, which will bring a combined 2.5 million square feet of research and development and advanced manufacturing space to a region that has become the No. 1 place where North America makes prescription drugs.

          advertisement

          One campus, called Pathway Triangle, is being built by a developer from Boston, King Street Properties. King Street — which has projects in Cambridge, Waltham, Allston, and Lexington — is building a similarly vast biomanufacturing campus in Devens. But these days it also sees a land of opportunity 700 miles to the south, in North Carolina.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Readout Newsletter: The latest on Moderna, Apellis, and Merck
          Readout Newsletter: The latest on Moderna, Apellis, and Merck

          JakubPorzycki/NurPhotoviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetou

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Bristol Myers buys into radiopharmaceuticals with RayzeBio

          CourtesyBristolMyersSquibbBristolMyersSquibbwillpay$4.1billionforRayzeBio,thecompaniessaidTuesday,bu